Key result
Metabolic syndrome and chronic simvastatin therapy were associated with more profound changes in cardiomyocyte stress markers before and after cardiopulmonary bypass.
Why the study?
Does chronic simvastatin therapy alter cardiomyocyte stress markers before and after cardiopulmonary bypass in patients with metabolic syndrome?
Observational (n=30)
Does chronic simvastatin therapy alter cardiomyocyte stress markers before and after cardiopulmonary bypass in patients with metabolic syndrome?
Chronic simvastatin therapy in patients with metabolic syndrome may exacerbate cardiomyocyte stress both before and after ischemia-reperfusion injury during cardiopulmonary bypass.
Answers are grounded in this paper and cite their sources.
Should not yet change simvastatin use in metabolic syndrome; hypothesis-generating for perioperative marker effects.
Metabolic syndrome (MetS) is a set of metabolic alterations including high levels of low-density lipoprotein (LDL), which increase the risk of cardiomyopathy often leading to surgery. Despite inducing myopathy, statins are widely used to lower LDL. Cardiopulmonary bypass (Cpb) causes oxidative stress and metabolic injury, altering mitochondrial expression (Grp75) and endoplasmic reticulum (Grp78) chaperones, apoptotic enzymes (Bcl2 family) and increasing cardiomyocyte lipid/lipofuscin storage. We believe that cardiomyocytes from patients with MetS may be more sensitive to surgical stress, in particular after simvastatin therapy (MetS+Stat). The study group included ten patients with MetS, ten patients with Mets+Stat and ten healthy subjects. Myocardial biopsies were obtained both before and after-Cpb. Grp75, Grp78, Bax, Bcl2, lipids, lipofuscin and fibrosis were evaluated by immuno/histochemistry. MetS cardiomyocytes had higher Grp75, Bax, fibrosis and lipofuscin. MetS+Stat had lower Grp75 and higher Grp78 expressions, high Bax, fewer fibrosis and higher lipofuscin content. Cpb did not vary the fibrosis and lipids/lipofuscin content, although it influenced the chaperones and Bax expression in all groups. These changes were more profound in patients with MetS and even more so in patients with MetS+Stat. The results suggest that MetS and MetS+Stat cardiomyocytes were more highly stressed after-Cpb. Interestingly, simvastatin caused high stress even before-Cpb.
No takes yet. Share an insight, caveat, or question.
Corsetti et al. (2012) conducted an observational in Metabolic syndrome and cardiopulmonary bypass (n=30). Metabolic syndrome and chronic simvastatin therapy vs. Healthy subjects and metabolic syndrome without statin therapy was evaluated on Cardiomyocyte stress markers (Grp75, Grp78, Bax, Bcl2, lipids, lipofuscin, and fibrosis). Metabolic syndrome and chronic simvastatin therapy were associated with more profound changes in cardiomyocyte stress markers before and after cardiopulmonary bypass.
Synapse has enriched 10 related papers. Consider them for comparative context: